The low prevalence of @entity301 in premenopausal @entity1 and its increase after menopause are well established. Although @entity172 is thought to play a role in protecting the vasculature, the mechanism has not been fully clarified. The contribution of platelets to atherosclerotic @entity65 is well recognized. The present study focused on the still-controversial effect of @entity172 on platelet function. We investigated the in vitro effects of @entity172 on @entity1 platelets, including their aggregation, @entity141 metabolism, the synthesis of @entity8613 , and NO ( @entity3542 / @entity1507 ) synthesis after stimulation with @entity556 or @entity857 . Pretreatment of platelets with @entity53 reduced the @entity1423 induced by @entity556 or @entity857 , whereas @entity42037 had no effect. @entity53 accelerated the recovery of [ @entity141 ]i after the agonist-induced peak and reduced the area under the curve of accumulated platelet [ @entity141 ]i but did not alter the baseline [ @entity141 ]i, @entity141 influx induced by @entity556 or @entity857 , the release of @entity141 from internal stores, or the size of internal @entity141 stores. Pretreatment of platelets with @entity53 had no effect on the intracellular concentration of @entity268 but increased that of cGMP in agonist-stimulated platelets. Additionally, @entity53 increased the platelet concentration of @entity3542 / @entity1507 in a dose-dependent manner. These effects of @entity53 on @entity1423 , @entity141 metabolism, and NO synthesis were abolished by exposure to @entity7293 , an NO synthesis inhibitor. These results suggest that @entity53 plays an important role in inhibiting @entity1423 by promoting @entity141 extrusion or reuptake activity that is dependent on the production of @entity6708 by increasing NO synthesis.

Effect of XXXX on inhibition of @entity1423 in vitro is mediated by an increase in NO synthesis.

@entity1 :: ('9606', 'Species') :: ['women', 'human'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity268 :: ('CHEBI:17489', 'Chemical') :: ['cAMP'] @entity6708 :: ('CHEBI:16356', 'Chemical') :: ['cGMP'] @entity556 :: ('2147', 'Gene') :: ['thrombin'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregation'] @entity42037 :: ('CHEBI:17160', 'Chemical') :: ['17alpha-estradiol'] @entity3542 :: ('CHEBI:16301', 'Chemical') :: ['nitrite'] @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['17Beta-estradiol', '17beta-estradiol'] @entity8613 :: ('MESH:D009712', 'Chemical') :: ['cyclic nucleotides'] @entity7293 :: ('CHEBI:28229', 'Chemical') :: ['N(G)-monomethyl-L-arginine'] @entity141 :: ('CHEBI:29108', 'Chemical') :: ['Ca2+'] @entity857 :: ('MESH:D000244', 'Chemical') :: ['ADP'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']
@entity53 :: (MESH:D004958,Chemical) :: ['17beta-estradiol']
